Vise Technologies Inc. Acquires New Holdings in Glaukos Corporation $GKOS

Vise Technologies Inc. bought a new position in shares of Glaukos Corporation (NYSE:GKOS) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 4,067 shares of the medical instruments supplier’s stock, valued at approximately $668,000.

Several other large investors have also recently bought and sold shares of the company. Quantinno Capital Management LP increased its holdings in shares of Glaukos by 964.0% in the first quarter. Quantinno Capital Management LP now owns 30,836 shares of the medical instruments supplier’s stock worth $3,320,000 after purchasing an additional 27,938 shares during the period. TimesSquare Capital Management LLC bought a new stake in Glaukos during the second quarter valued at $20,293,000. BlackRock Inc. bought a new stake in Glaukos during the second quarter valued at $1,333,318,000. Susquehanna Fundamental Investments LLC bought a new stake in Glaukos during the second quarter valued at $3,361,000. Finally, Wellington Management Group LLP grew its position in Glaukos by 187.1% during the second quarter. Wellington Management Group LLP now owns 428,215 shares of the medical instruments supplier’s stock worth $59,847,000 after buying an additional 279,065 shares in the last quarter. 99.04% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on GKOS. BTIG Research upped their target price on Glaukos from $205.00 to $234.00 and gave the stock a “buy” rating in a research note on Thursday, October 29th. Piper Sandler reiterated an “overweight” rating and set a $240.00 price target (up from $195.00) on shares of Glaukos in a research report on Thursday, October 29th. Weiss Ratings reissued a “sell (d-)” rating on shares of Glaukos in a report on Thursday, October 15th. Zacks Research upgraded shares of Glaukos from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, October 28th. Finally, Jefferies Financial Group upped their price objective on shares of Glaukos from $190.00 to $210.00 and gave the stock a “buy” rating in a research report on Tuesday, September 22nd. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $216.71.

Insider Activity

In other news, Director Gilbert Kliman sold 2,500 shares of the stock in a transaction dated Wednesday, November 4th. The stock was sold at an average price of $253.00, for a total transaction of $632,500.00. Following the transaction, the director directly owned 37,406 shares in the company, valued at approximately $9,463,718. This represents a 6.26% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 5.90% of the company’s stock.

Glaukos Stock Performance

NYSE GKOS opened at $236.81 on Wednesday. Glaukos Corporation has a 52-week low of $87.32 and a 52-week high of $255.18. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.09 and a current ratio of 4.57. The company has a market capitalization of $14.02 billion, a P/E ratio of -80.55 and a beta of 0.68. The company has a fifty day moving average of $180.57 and a 200-day moving average of $145.22.

Glaukos (NYSE:GKOS) last announced its earnings results on Wednesday, October 28th. The medical instruments supplier reported $0.47 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.57. Glaukos had a negative net margin of 24.60% and a negative return on equity of 0.97%. The company had revenue of $211.03 million during the quarter, compared to analyst estimates of $168.04 million. During the same period in the previous year, the business earned ($0.16) earnings per share. The firm’s quarterly revenue was up 58.0% compared to the same quarter last year. As a group, equities research analysts predict that Glaukos Corporation will post 0.50 EPS for the current fiscal year.

Glaukos Profile

Glaukos Corporation is an ophthalmic medical technology company that develops and commercializes treatments for glaucoma and other eye disorders. Its portfolio includes minimally invasive glaucoma surgery (MIGS) devices, such as the iStent family, and iDose TR, an implant designed to deliver glaucoma medication inside the eye over an extended period. The company also offers products for corneal disorders, including technology used in corneal cross-linking procedures to treat keratoconus and other conditions that weaken the cornea.